ClinicalTrials.gg
RecruitingNCT07132463Updated Sep 21, 2026

Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

A Phase 3 interventional study of Long-course chemoradiotherapy and Tislelizumab combined with the CAPOX regimen in Rectal Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Rectal Neoplasms by Fudan University — 22 open to participants now, 22 under way, 3 of them phase 3. Rectal Neoplasms · Fudan University.

Planned enrollment
15th of 41
196 · median 134
Started
2025
with 4 others
Phase 3
4 of 43
3 open now
Primary completion
2027-12
later than 13 of 21 live
Registered
37th of 43
by date

Among the 43 studies in Rectal Neoplasms by Fudan University, this one is the 15th largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 13 of the 21 other live ones, and was the 37th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

22 of the 43 studies in Rectal Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Rectal Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This open-label, multicenter, randomized controlled trial involved 196 patients with pathologically confirmed, previously untreated, resectable MSI-L or MSS/pMMR ultra-low rectal adenocarcinoma. Patients were randomly assigned (1:1) to two groups to receive concurrent chemoradiotherapy followed by 4-6 cycles of chemotherapy ± tislelizumab. After treatment, patients who achieved complete clinical response (cCR), including those who reached pCR after local excision, or near cCR with pCR after local excision, were recommended to continue with 4-2 cycles of chemotherapy ± tislelizumab, followed by a watch-and-wait approach. Patients evaluated as incomplete responders were recommended for total mesorectal excision (TME) surgery. The primary endpoint is the anus preservation rate, while secondary endpoints include CR rate, 1-year/2-year/3-year organ preservation rates, 1-year/2-year/3-year EFS rates, and 1-year/2-year/3-year OS rates, etc.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Ultra-low Rectal Cancer
  • Tislelizumab
  • Neoadjuvant Chemoradiotherapy
  • Anus Preservation
  • PD-1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written , understand, and comply with the requirements and evaluation schedule.
  2. Age ≥18 and ≤75 years old.
  3. confirmed rectal adenocarcinoma.
  4. Immunohistochemistry confirmed pMMR (positive for MLH1, MSH2, MSH6, and PMS2), or PCR/NGS confirmed MSI-L or MSS.
  5. Tumor distal margin confirmed to be ≤ 3 cm from the anal verge by colonoscopy, digital rectal examination, or MRI.
  6. Clinical stage cT1-3N1M0 or cT3N0M0 (the 8th UICC/AJCC; T and N evaluated by MRI).
  7. Resectable primary tumor assessed by the Investigator.
  8. No prior anti-tumor treatment for rectal cancer.
  9. (ECOG) performance status score ≤ 1.
  10. Adequate organ function.
  11. Female subjects with the ability to become pregnant must have a serum pregnancy test with a negative result within 72 hours before the first dose and be willing to use highly effective methods during the trial and for 120 days after the last dose. Male subjects whose partners are women of should be surgically sterilized or agree to use a highly effective method of contraception during the trial and for 120 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. confirmed poorly differentiated/undifferentiated adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma.
  2. Previously received treatment for rectal cancer or have evidence of distant .
  3. Presence of the following high-risk factors assessed by MRI: MRF+, EMVI+, cN2, positive lateral lymph nodes, T3d.
  4. Presence of or at high risk for obstruction, perforation, or bleeding.
  5. Unsuitability for long-course radiotherapy.
  6. Inability to tolerate surgery.
  7. ≥ 2 colorectal cancer lesions at the same time.
  8. for MRI examination.
  9. Other malignant tumors in the past or currently present.
  10. Active disease requiring systemic therapy within the past 2 years.
  11. infection.
  12. Untreated chronic or chronic hepatitis B virus (HBV) carriers (HBV DNA > 500 IU/mL) or active carriers with detectable HCV RNA.
  13. to any ingredient of tislelizumab, capecitabine, and oxaliplatin, or to any component of their containers.
  14. Other conditions judged by the researcher as not meeting the enrollment requirements.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    Concurrent Chemoradiotherapy Followed by Chemotherapy Plus Immunotherapy Group

    Long-course chemoradiotherapy followed by 4 cycles of CAPOX and Tislelizumab. (Note: Patients evaluated as ncCR after completion, if refusing local excision, may receive an additional 2 cycles of CAPOX and Tislelizumab before re-evaluation.)

    Radiation: Long-course chemoradiotherapy · Drug: Tislelizumab combined with the CAPOX regimen

  • Active comparator
    Concurrent Chemoradiotherapy Followed by Chemotherapy Group

    Long-course chemoradiotherapy followed by 4 cycles of CAPOX. (Note: Patients evaluated as ncCR after completion, if refusing local excision, may receive an additional 2 cycles of CAPOX before re-evaluation.)

    Radiation: Long-course chemoradiotherapy · Drug: CAPOX regimen

Interventions

  • RadiationLong-course chemoradiotherapy

    45-50.4 Gy in 25-28 fractions to the pelvis on Days 1-5 each week. Capecitabine at a dose of 825 mg/m², taken orally twice daily (bid), 5 days per week during radiotherapy.

  • DrugTislelizumab combined with the CAPOX regimen

    Tislelizumab 200 mg IV on Day 1 of each 21-day cycle. Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle. Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle.

  • DrugCAPOX regimen

    Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle. Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Anus preservation rate

    Defined as the anus preservation rate in the efficacy-evaluable analysis set of patients, as assessed by the investigators.

    Time frame: From first dose of radiotherapy up to approximately 24/32±4 weeks.

Secondary outcomes

  1. Complete Response rate (CR Rate)

    Defined as the proportion of participants with clinical complete response (cCR) and pathologic complete response (pCR), determined by the investigators.

    Time frame: From first dose of radiotherapy up to approximately 24/32±4 weeks.

  2. 1/2/3-Year Organ-Preservation Rate

    Defined as the proportion of participants who survived and did not undergo TME at 1, 2, and 3 years.

    Time frame: From first dose of radiotherapy up to approximately 36 months.

  3. 1/2/3-Year EFS Rate

    Defined as the proportion of participants who did not develop local recurrence, distant metastasis, new invasive primary lesions of colorectal cancer, or death at 1, 2, and 3 years.

    Time frame: From first dose of radiotherapy up to approximately 36 months.

  4. 1/2/3-Year OS Rate

    Defined as the proportion of participants who survived at 1, 2, and 3 years.

    Time frame: From first dose of radiotherapy up to approximately 36 months.

  5. Percentage of Participants With Adverse Events

    Percentage of participants with adverse events (AEs), immune-related adverse events(irAE), and serious adverse events (SAEs).

    Time frame: From first dose of radiotherapy up to approximately 36 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 28 months is below that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 20, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2030
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07132463
Lead sponsor
Fudan University
Responsible party
Xu jianmin (Chief Physician, Fudan University) — Principal investigator
First posted
Aug 20, 2025
Start date
Aug 12, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 21, 2026

Study contacts

Jianmin Xu, MD
Contact
xujmin@aliyun.com
86-21-64041990
Wentao Tang, MD
Contact
tangwt1988@163.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion